Cardiff Oncology Announces Fourth Quarter and Full Year 2020 Results and Recent Highlights
News provided by
Share this article
SAN DIEGO, Feb. 25, 2021 /PRNewswire/
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer, castrate-resistant prostate cancer and leukemias, today announced recent company highlights and financial results for the fourth quarter and full year ended December 31, 2020. Over the last several months we achieved key clinical milestones, which provided the momentum for our successful raise of over $100 million. Together, these events have enabled us to accelerate the execution of our clinical programs and expand our pipeline to other relevant cancer indications, said Dr. Mark Erlander, chief executive officer of Cardiff Oncology. Data from our lead KRAS-mutated metastatic color
11
Clinical oncology next generation sequencing market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to grow at a CAGR of 13.90% in the above mentioned forecast period.
Clinical Oncology Next Generation Sequencing market research report utilizes the graphs and charts which turns it into more visually appealing. This makes available the best way to the users to understand customer and thus increase their satisfaction by answering the needs and expectations. It also helps to see what factors are influencing the business, where the brand is situated, and get the temperature of the market before a product is launched. Once all the market analysis and studies are done, it is time to present them efficiently, so as to onboard everyone and make the right decisions for the business strategy market research reports are the key partners in the matter.